Sugi Predict

Sugi Predict / Targets / IP6K1

IP6K1

Inositol hexakisphosphate kinase 1 · Q92551 · IP6K1 on Sugi Atlas →

15,844 patent compounds predicted against IP6K1, 7,411 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL642178 SCHEMBL642178 0.58 9/20
SCHEMBL263154 SCHEMBL263154 0.54 9/20
SCHEMBL182871 SCHEMBL182871 0.58 8/20
SCHEMBL216176 SCHEMBL216176 0.58 8/20
SCHEMBL1360723 SCHEMBL1360723 0.54 8/20
SCHEMBL496967 SCHEMBL496967 0.65 7/20
SCHEMBL158065 SCHEMBL158065 0.53 7/20
SCHEMBL527853 SCHEMBL527853 0.51 7/20
SCHEMBL1193310 SCHEMBL1193310 0.47 7/20
SCHEMBL327387 SCHEMBL327387 0.42 7/20
SCHEMBL1507614 SCHEMBL1507614 0.63 6/20
SCHEMBL1257333 SCHEMBL1257333 0.61 6/20
SCHEMBL1444275 SCHEMBL1444275 0.59 6/20
SCHEMBL858674 SCHEMBL858674 0.58 6/20
SCHEMBL858781 SCHEMBL858781 0.56 6/20
SCHEMBL641597 SCHEMBL641597 0.56 6/20
SCHEMBL256397 SCHEMBL256397 0.49 6/20
SCHEMBL157952 SCHEMBL157952 0.46 6/20
SCHEMBL669366 SCHEMBL669366 0.54 5/20
SCHEMBL1178698 SCHEMBL1178698 0.54 5/20

Clinical trials — most relevant to IP6K1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes PHASE4COMPLETED
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients PHASE3COMPLETED
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus PHASE2/PHASE3UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
Inositol in Letrozol Resistant PCOS Women PHASE2/PHASE3COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study nanWITHDRAWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans nanCOMPLETED
Myoinositol Treatment and Asprosin Levels in PCOS nanCOMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IP6K1 binder may also engage these)

ProteinNameSimilarity
Q9ESM0 — 0.999 Q9ESM0 →
Q6PD10 — 0.998 Q6PD10 →
Q99NI4 — 0.957 Q99NI4 →
Q7TT16 — 0.955 Q7TT16 →
IPMK Inositol polyphosphate multikinase 0.949 landscape →
Q9R0U1 — 0.949 Q9R0U1 →
IP6K2 Inositol hexakisphosphate kinase 2 0.948 landscape →
Q0P5F7 — 0.947 Q0P5F7 →
O54804 — 0.947 O54804 →
Q95221 — 0.946 Q95221 →
METTL16 RNA N(6)-adenosine-methyltransferase METTL16 0.944 landscape →
Q91YD4 — 0.943 Q91YD4 →
Q01134 — 0.943 Q01134 →
Q91XU3 — 0.942 Q91XU3 →
Q80YA3 — 0.942 Q80YA3 →
Q8TBP0 — 0.941 Q8TBP0 →
PIP4K2C Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma 0.941 landscape →
Q5ZIA0 — 0.941 Q5ZIA0 →
Q2PFX0 — 0.939 Q2PFX0 →
Q9CQG2 — 0.939 Q9CQG2 →
Q5R488 — 0.938 Q5R488 →
Q8NHH1 — 0.938 Q8NHH1 →
CHKB Choline/ethanolamine kinase 0.938 landscape →
E1C1R4 — 0.937 E1C1R4 →
Q9QZC1 — 0.937 Q9QZC1 →
Q6P5H6 — 0.937 Q6P5H6 →
O88370 — 0.937 O88370 →
Q4V8I4 — 0.937 Q4V8I4 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.936 landscape →
E9PTA2 — 0.936 E9PTA2 →